Index -
P/E -
EPS (ttm) -0.14
Insider Own 14.07%
Shs Outstand 80.60M
Perf Week 0.09%
Market Cap 4.03B
Forward P/E 16.25
EPS next Y 2.68
Insider Trans -39.26%
Shs Float 79.53M
Perf Month 2.09%
Income 58.69M
PEG -
EPS next Q 0.45
Inst Own 64.23%
Short Float 2.97%
Perf Quarter -0.18%
Sales 2.57B
P/S 1.57
EPS this Y 29.64%
Inst Trans 1.82%
Short Ratio 2.94
Perf Half Y 35.83%
Book/sh 7.15
P/B 6.09
EPS next Y 31.67%
ROA 0.66%
Short Interest 2.36M
Perf Year 56.75%
Cash/sh 11.93
P/C 3.65
EPS next 5Y 31.09%
ROE 9.55%
52W Range 24.74 - 47.20
Perf YTD 0.90%
Dividend Est. 1.73 (3.98%)
P/FCF 7.63
EPS past 5Y -
ROI 3.01%
52W High -7.71%
Beta 1.55
Dividend TTM 1.34 (3.08%)
Quick Ratio -
Sales past 5Y 29.25%
Gross Margin 97.16%
52W Low 76.07%
ATR (14) 1.32
Dividend Ex-Date May 17, 2024
Current Ratio -
EPS Y/Y TTM -14.09%
Oper. Margin 1.54%
RSI (14) 49.79
Volatility 3.42% 2.88%
Employees 1850
Debt/Eq 1.71
Sales Y/Y TTM 69.76%
Profit Margin 2.28%
Recom 2.14
Target Price 47.69
Option/Short Yes / Yes
LT Debt/Eq 1.71
EPS Q/Q -1342.47%
Payout -
Rel Volume 0.69
Prev Close 42.38
Sales Surprise 0.46%
EPS Surprise 14.43%
Sales Q/Q 28.80%
Earnings May 08 BMO
Avg Volume 802.83K
Price 43.56
SMA20 0.26%
SMA50 -1.42%
SMA200 17.64%
Trades
Volume 556,731
Change 2.78%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-24 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$43 → $52
Jan-04-24 Initiated
TD Cowen
Market Perform
$38
Dec-06-23 Resumed
BMO Capital Markets
Market Perform
$36
Nov-30-23 Resumed
Goldman
Buy
$43
May-19-23 Initiated
Citigroup
Buy
$32
Jan-24-23 Downgrade
JP Morgan
Overweight → Neutral
$35 → $34
Oct-19-22 Initiated
Credit Suisse
Neutral
$27.50
Oct-17-22 Initiated
Jefferies
Hold
$30
Oct-14-22 Downgrade
Exane BNP Paribas
Outperform → Neutral
$32
Jun-08-22 Initiated
JMP Securities
Mkt Perform
May-08-24 12:54PM
09:25AM
08:00AM
May-02-24 01:00PM
May-01-24 10:01AM
12:10PM
Loading…
Apr-24-24 12:10PM
Apr-17-24 09:00AM
Apr-15-24 09:02AM
(The Wall Street Journal)
Apr-04-24 08:00AM
Apr-03-24 08:00AM
Mar-29-24 01:13AM
Mar-24-24 11:00AM
Mar-07-24 10:05AM
(The Wall Street Journal)
Mar-04-24 09:40AM
Mar-01-24 11:36PM
05:25PM
Loading…
Feb-29-24 05:25PM
09:19AM
Feb-28-24 09:10PM
Feb-27-24 08:50AM
Feb-26-24 09:11AM
06:25AM
Feb-21-24 09:06AM
Feb-20-24 01:46PM
Feb-19-24 01:16PM
Feb-14-24 08:00AM
Feb-13-24 09:25AM
08:00AM
Feb-06-24 10:00AM
Feb-05-24 10:27AM
Jan-24-24 06:32PM
04:58PM
Loading…
Jan-23-24 04:58PM
08:47AM
08:00AM
Jan-18-24 05:46PM
Jan-16-24 03:48PM
(The Wall Street Journal)
09:00AM
Jan-11-24 08:00AM
Jan-10-24 08:00AM
Dec-27-23 07:47AM
Dec-18-23 01:24PM
Dec-15-23 07:55AM
Dec-01-23 06:06AM
Nov-21-23 08:00AM
Nov-07-23 03:20PM
(The Wall Street Journal)
08:00AM
05:30AM
(The Wall Street Journal)
Nov-06-23 08:33AM
Nov-02-23 07:00AM
Oct-11-23 08:00AM
Oct-02-23 08:00AM
Sep-25-23 01:33PM
Sep-20-23 12:13AM
Sep-19-23 09:00AM
Sep-13-23 08:30AM
Sep-05-23 12:31PM
08:00AM
Aug-28-23 12:00PM
Aug-12-23 08:04AM
Aug-09-23 08:40AM
Aug-08-23 08:00AM
Jul-31-23 01:39PM
(The Wall Street Journal)
Jul-27-23 04:05PM
Jul-19-23 11:31AM
Jul-11-23 08:30AM
Jul-10-23 07:00AM
Jun-09-23 08:18AM
Jun-05-23 08:30AM
May-18-23 07:12AM
May-17-23 04:31PM
(The Wall Street Journal)
May-15-23 03:54PM
(The Wall Street Journal)
06:30AM
06:30AM
May-03-23 09:00AM
May-02-23 04:30PM
Apr-20-23 08:30AM
Apr-04-23 12:00PM
Mar-31-23 06:30AM
(The Wall Street Journal)
Feb-16-23 06:31AM
Feb-15-23 08:00AM
Jan-18-23 08:30AM
Jan-10-23 10:00AM
Jan-09-23 04:56AM
(The Wall Street Journal)
Nov-29-22 06:00AM
(The Wall Street Journal)
Nov-22-22 08:00AM
Nov-11-22 06:01AM
Nov-09-22 08:04AM
(The Wall Street Journal) +9.42%
08:00AM
Oct-25-22 09:00AM
Oct-24-22 09:15AM
Oct-12-22 08:30AM
Oct-04-22 06:00AM
(The Wall Street Journal) +6.11%
Oct-03-22 10:37AM
(The Wall Street Journal)
Aug-22-22 12:00PM
Aug-19-22 06:00AM
(The Wall Street Journal)
Aug-18-22 07:55AM
Aug-17-22 11:39AM
Aug-12-22 06:00AM
(The Wall Street Journal)
Aug-09-22 01:49PM
(The Wall Street Journal)
12:12PM
(American City Business Journals)
08:17AM
TPG, Inc. operates as a global, diversified alternative asset management firm. It invests across five multi-product platforms: Capital, Growth, Impact, Real Estate, and Market Solutions. The firm aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. The company was founded by Jim Coulter and David Bonderman in 1992 and is headquartered in Fort Worth, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BONDERMAN DAVID Director Feb 29 '24 Sale 41.64 1,584,746 65,988,823 0 Feb 29 06:18 PM COULTER JAMES G Executive Chairman Feb 29 '24 Sale 41.64 1,334,746 55,578,823 0 Feb 29 06:24 PM WINKELRIED JON Chief Executive Officer Feb 29 '24 Sale 41.64 1,000,000 41,640,000 3,326,460 Feb 29 07:01 PM COSLET JONATHAN J Director Feb 29 '24 Sale 41.64 1,000,000 41,640,000 0 Feb 29 06:22 PM Davis Kelvin L. Director Feb 29 '24 Sale 41.64 822,017 34,228,788 844,584 Feb 29 06:29 PM Sisitsky Todd Benjamin President Feb 29 '24 Sale 41.64 660,151 27,488,688 512,766 Feb 29 06:43 PM Rhodes Jeffrey K. Director Feb 29 '24 Sale 41.64 408,675 17,017,227 176,492 Feb 29 06:38 PM Trujillo David Director Feb 29 '24 Sale 41.64 397,510 16,552,316 182,519 Feb 29 06:45 PM Weingart Jack Chief Financial Officer Feb 29 '24 Sale 41.64 308,468 12,844,608 775,982 Feb 29 06:57 PM Raj Nehal Director Feb 29 '24 Sale 41.64 250,858 10,445,727 549,712 Feb 29 06:36 PM Sarvananthan Ganendran Director Feb 29 '24 Sale 41.64 172,705 7,191,436 42,388 Feb 29 06:41 PM Vazquez-Ubarri Anilu Chief Operating Officer Feb 29 '24 Sale 41.64 101,937 4,244,657 333,711 Feb 29 07:23 PM Berenson Bradford General Counsel Feb 29 '24 Sale 41.64 90,895 3,784,868 196,252 Feb 29 06:15 PM Chorengel Maya Director Feb 29 '24 Sale 41.64 74,773 3,113,548 57,146 Feb 29 06:20 PM Sisitsky Todd Benjamin President Feb 29 '24 Sale 41.64 52,807 2,198,883 396,982 Feb 29 06:43 PM WINKELRIED JON Chief Executive Officer Feb 29 '24 Sale 41.64 50,848 2,117,311 0 Feb 29 07:01 PM Davidson Martin Chief Accounting Officer Feb 29 '24 Sale 41.64 39,317 1,637,160 30,991 Feb 29 06:26 PM Harris Joann Chief Compliance Officer Feb 29 '24 Sale 41.64 23,745 988,742 0 Feb 29 06:33 PM COULTER JAMES G Executive Chairman Feb 29 '24 Sale 41.64 16,949 705,756 386,936 Feb 29 06:24 PM BONDERMAN DAVID Director Feb 29 '24 Sale 41.64 16,949 705,756 37,967 Feb 29 06:18 PM Harris Joann Chief Compliance Officer Feb 29 '24 Sale 41.64 1,739 72,412 22,860 Feb 29 06:33 PM MESSEMER DEBORAH M. Director Feb 28 '24 Sale 43.97 6,390 280,980 18,033 Mar 01 05:14 PM WINKELRIED JON Chief Executive Officer Feb 27 '24 Option Exercise 0.00 1,000,000 0 4,326,460 Feb 29 07:01 PM Weingart Jack Chief Financial Officer Feb 27 '24 Option Exercise 0.00 308,468 0 1,084,450 Feb 29 06:57 PM Sisitsky Todd Benjamin President Feb 27 '24 Option Exercise 0.00 660,151 0 1,172,917 Feb 29 06:43 PM Trujillo David Director Feb 27 '24 Option Exercise 0.00 397,510 0 580,029 Feb 29 06:45 PM Raj Nehal Director Feb 27 '24 Option Exercise 0.00 250,858 0 800,570 Feb 29 06:36 PM Harris Joann Chief Compliance Officer Feb 27 '24 Option Exercise 0.00 23,745 0 23,745 Feb 29 06:33 PM Sarvananthan Ganendran Director Feb 27 '24 Option Exercise 0.00 162,707 0 215,093 Feb 29 06:41 PM Rhodes Jeffrey K. Director Feb 27 '24 Option Exercise 0.00 408,675 0 585,167 Feb 29 06:38 PM Davis Kelvin L. Director Feb 27 '24 Option Exercise 0.00 822,017 0 1,666,601 Feb 29 06:29 PM Davidson Martin Chief Accounting Officer Feb 27 '24 Option Exercise 0.00 39,317 0 70,308 Feb 29 06:26 PM Vazquez-Ubarri Anilu Chief Operating Officer Feb 27 '24 Option Exercise 0.00 101,937 0 435,648 Feb 29 07:23 PM BONDERMAN DAVID Director Feb 27 '24 Option Exercise 0.00 1,500,000 0 1,516,949 Feb 29 06:18 PM Berenson Bradford General Counsel Feb 27 '24 Option Exercise 0.00 90,895 0 287,147 Feb 29 06:15 PM Chorengel Maya Director Feb 27 '24 Option Exercise 0.00 69,298 0 131,919 Feb 29 06:20 PM COULTER JAMES G Executive Chairman Feb 27 '24 Option Exercise 0.00 1,250,000 0 1,266,949 Feb 29 06:24 PM COSLET JONATHAN J Director Feb 27 '24 Option Exercise 0.00 1,000,000 0 1,000,000 Feb 29 06:22 PM
Index RUT
P/E -
EPS (ttm) -1.79
Insider Own 34.30%
Shs Outstand 170.72M
Perf Week 7.97%
Market Cap 508.75M
Forward P/E -
EPS next Y -1.61
Insider Trans -0.03%
Shs Float 112.16M
Perf Month -14.86%
Income -290.08M
PEG -
EPS next Q -0.37
Inst Own 59.68%
Short Float 30.20%
Perf Quarter -39.18%
Sales 0.13M
P/S 3913.43
EPS this Y 24.69%
Inst Trans 5.02%
Short Ratio 15.39
Perf Half Y 23.14%
Book/sh 2.71
P/B 1.10
EPS next Y -2.05%
ROA -43.52%
Short Interest 33.87M
Perf Year -55.79%
Cash/sh 2.25
P/C 1.32
EPS next 5Y 1.00%
ROE -55.06%
52W Range 2.23 - 6.89
Perf YTD -7.17%
Dividend Est. -
P/FCF -
EPS past 5Y 22.18%
ROI -52.72%
52W High -56.75%
Beta 0.90
Dividend TTM -
Quick Ratio 12.80
Sales past 5Y -27.79%
Gross Margin -7505.91%
52W Low 33.63%
ATR (14) 0.27
Dividend Ex-Date -
Current Ratio 12.80
EPS Y/Y TTM 26.64%
Oper. Margin -219123.85%
RSI (14) 40.56
Volatility 12.05% 7.99%
Employees -
Debt/Eq 0.21
Sales Y/Y TTM -24.70%
Profit Margin -223140.00%
Recom 1.65
Target Price 11.68
Option/Short Yes / Yes
LT Debt/Eq 0.19
EPS Q/Q 43.72%
Payout -
Rel Volume 1.58
Prev Close 2.96
Sales Surprise 96.43%
EPS Surprise 7.23%
Sales Q/Q -57.69%
Earnings May 13 AMC
Avg Volume 2.20M
Price 2.98
SMA20 -1.84%
SMA50 -22.89%
SMA200 -17.00%
Trades
Volume 3,479,390
Change 0.68%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-24 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Jan-05-24 Downgrade
Guggenheim
Buy → Neutral
Dec-08-23 Initiated
Citigroup
Buy
$7
Dec-08-23 Initiated
Citigroup
Buy
Jun-26-23 Resumed
Oppenheimer
Outperform
$28
Mar-21-23 Initiated
Bernstein
Mkt Perform
$6
Jan-24-23 Upgrade
JP Morgan
Neutral → Overweight
$20 → $11
Jan-06-23 Upgrade
Robert W. Baird
Neutral → Outperform
$12
Dec-12-22 Downgrade
BofA Securities
Buy → Underperform
$24 → $9
Aug-10-22 Downgrade
Raymond James
Outperform → Mkt Perform
Jul-15-22 Upgrade
Goldman
Neutral → Buy
$9 → $32
Jun-03-22 Initiated
Robert W. Baird
Neutral
$11
Feb-28-22 Reiterated
B. Riley Securities
Buy
$30 → $21
Oct-20-21 Initiated
Cowen
Outperform
Oct-08-21 Downgrade
Stifel
Buy → Hold
$44 → $18
Oct-08-21 Downgrade
Goldman
Buy → Neutral
$71 → $20
Sep-23-21 Upgrade
Raymond James
Mkt Perform → Outperform
Jun-21-21 Resumed
Jefferies
Buy
$53
May-20-21 Upgrade
Truist
Hold → Buy
$34 → $41
May-14-21 Initiated
B. Riley Securities
Buy
$52
Show Previous Ratings
May-14-24 12:56PM
09:14AM
08:21AM
03:06AM
May-13-24 08:55PM
05:36PM
Loading…
05:36PM
05:10PM
04:47PM
04:17PM
(Associated Press Finance)
04:14PM
04:01PM
May-06-24 08:30AM
Apr-26-24 10:32AM
08:30AM
Apr-24-24 10:01AM
02:45PM
Loading…
Apr-11-24 02:45PM
Apr-09-24 08:30AM
Apr-08-24 08:46AM
Mar-16-24 04:35PM
Mar-15-24 09:32AM
07:04AM
(Thomson Reuters StreetEvents)
Mar-14-24 08:55PM
05:34PM
05:15PM
04:15PM
(Associated Press Finance)
04:05PM
Mar-13-24 12:15PM
Mar-12-24 08:50AM
08:30AM
Mar-05-24 09:55AM
08:30AM
Loading…
08:30AM
Feb-28-24 08:30AM
Feb-16-24 08:30AM
Jan-16-24 04:05PM
Jan-12-24 08:34AM
Jan-05-24 12:52PM
08:25AM
08:13AM
Jan-04-24 04:15PM
04:05PM
11:05AM
Jan-03-24 04:05PM
Dec-09-23 12:00PM
Dec-01-23 08:30AM
Nov-24-23 06:40AM
Nov-10-23 12:00PM
Nov-03-23 12:15PM
12:00PM
12:00PM
10:15AM
Nov-02-23 07:33PM
04:12PM
(Associated Press Finance)
04:02PM
09:00AM
Oct-30-23 08:30AM
Oct-26-23 08:30AM
Oct-16-23 09:26AM
08:30AM
Sep-27-23 09:09AM
Sep-25-23 08:45AM
Sep-05-23 08:30AM
Aug-29-23 07:30AM
Aug-23-23 12:26PM
Aug-17-23 08:44AM
Aug-14-23 08:30AM
Aug-03-23 11:20AM
Aug-02-23 05:25PM
04:13PM
04:02PM
10:41AM
Jul-26-23 08:30AM
Jun-15-23 09:30AM
Jun-14-23 08:00AM
Jun-09-23 06:25PM
08:02AM
Jun-03-23 09:00AM
Jun-02-23 11:31AM
May-31-23 12:02PM
10:46AM
May-29-23 07:48AM
May-26-23 10:51AM
09:55AM
08:23AM
May-25-23 03:16PM
May-24-23 11:37AM
08:30AM
08:14AM
May-22-23 08:16AM
May-19-23 11:16AM
10:24AM
May-18-23 04:37PM
12:45PM
11:15AM
May-17-23 02:19PM
11:21AM
11:13AM
May-16-23 09:31AM
May-12-23 12:08PM
11:34AM
10:04AM
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Parker Geoffrey M. CHIEF FINANCIAL OFFICER Jan 30 '24 Buy 3.60 190 683 819,590 Mar 06 09:52 PM MESSEMER DEBORAH M. Director Dec 18 '23 Sale 2.70 18,640 50,317 62,456 Dec 20 04:26 PM Mayo Stephen Director Aug 07 '23 Sale 4.29 10,000 42,855 25,328 Aug 09 04:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite